Rakovina Therapeutics to present AI-driven brain cancer research at Neuro-Oncology Conference

Rakovina Therapeutics Inc (TSX-V:RKV) will present preliminary results of its AI-driven drug development program at the Neuro-Oncology Annual Meeting in Houston on November 22, 2024. The virtual poster, titled “Utilizing Artificial Intelligence for the Discovery of Novel PARP1-Selective Inhibitors for Use Against Brain Tumors,” highlights the use of AI to design therapies targeting PARP1, a key protein in DNA repair. This innovative approach aims to create more effective treatments for aggressive brain cancers, such as glioblastomas, while sparing healthy cells.